Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis

• Main Authors: Mohamed‐Eslam F. Mohamed (Author), Yuli Qian (Author), Ronilda D'Cunha (Author), Teresa Sligh (Author), Laura K. Ferris (Author), Ann Eldred (Author), Gweneth F. Levy (Author), Shuai Hao (Author), Shashikanth Gannu (Author), David G. Rizzo (Author), Wei Liu (Author), Sasha Jazayeri (Author), Howard Sofen (Author), Roberto Carcereri De Prati (Author)
• Format: Book
• Published: Wiley, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Cedirogant is an inverse agonist of retinoic acid‐related orphan receptor gamma thymus (RORγt) developed for the treatment of moderate to severe chronic plaque psoriasis. Here, we report the results from two phase I studies in which the pharmacokinetics (PK), safety, and efficacy of cedirog...